Trial Profile
Post-Marketing Surveillance of REMSIMA 100 mg. (Infliximab)(monoclonal antibody, recombinant) to Evaluate its Safety and Efficacy in Thailand
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2019
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- 15 Jan 2019 Status changed from not yet recruiting to recruiting.
- 21 Dec 2017 New trial record